24,591 Colgate-Palmolive Company $CL Shares Purchased by Hamel Associates Inc.

Hamel Associates Inc. lifted its position in Colgate-Palmolive Company (NYSE:CL – Free Report) by 524.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,281 shares of the company’s stock after acquiring an additional 24,591 shares during the quarter. Hamel Associates Inc.’s holdings in Colgate-Palmolive were worth $2,498,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CL. Moors & Cabot Inc. grew its stake in Colgate-Palmolive by 1.0% in the 3rd quarter. Moors & Cabot Inc. now owns 42,266 shares of the company’s stock valued at $3,606,000 after purchasing an additional 409 shares during the period. Money Concepts Capital Corp grew its stake in shares of Colgate-Palmolive by 2.6% during the 3rd quarter. Money Concepts Capital Corp now owns 47,726 shares of the company’s stock worth $4,072,000 after acquiring an additional 1,220 shares during the period. Allworth Financial LP grew its stake in shares of Colgate-Palmolive by 17.9% during the 3rd quarter. Allworth Financial LP now owns 38,674 shares of the company’s stock worth $3,546,000 after acquiring an additional 5,870 shares during the period. Fisher Asset Management LLC increased its holdings in Colgate-Palmolive by 64.0% in the 3rd quarter. Fisher Asset Management LLC now owns 100,653 shares of the company’s stock worth $8,588,000 after acquiring an additional 39,268 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Colgate-Palmolive by 18.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,651,979 shares of the company’s stock worth $141,843,000 after acquiring an additional 251,887 shares during the last quarter. Institutional investors own 80.41% of the company’s stock.

Latest Colgate-Palmolive News

Here’s some of the latest news about CL:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85, close to the $3.92 consensus, and nudged its FY2027 and FY2028 forecasts higher to $4.06 and $4.38, respectively. These revisions suggest modest confidence in longer-term earnings growth. Zacks Research Has Bullish Forecast for CL FY2026 Earnings
  • Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading global oral-care position and its pet-nutrition business as potential growth diversifiers, but the article did not report a new company-specific catalyst. Colgate-Palmolive vs. Kimberly-Clark
  • Negative Sentiment: A Colgate-Palmolive executive vice president sold $401,677 worth of company shares. Insider sales can weigh on sentiment, although a single transaction does not necessarily indicate a change in the company’s outlook. Insider Selling: Colgate-Palmolive EVP Sells Stock

Insider Activity at Colgate-Palmolive

In other news, insider John Hazlin sold 23,376 shares of Colgate-Palmolive stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $99.15, for a total transaction of $2,317,730.40. Following the completion of the sale, the insider directly owned 27,021 shares of the company’s stock, valued at approximately $2,679,132.15. The trade was a 46.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Noel R. Wallace sold 20,000 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $100.26, for a total transaction of $2,005,200.00. Following the completion of the transaction, the chief executive officer owned 359,700 shares of the company’s stock, valued at $36,063,522. This trade represents a 5.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 77,414 shares of company stock worth $7,613,786 in the last 90 days. 0.43% of the stock is currently owned by corporate insiders.

Colgate-Palmolive Stock Down 0.1%

CL opened at $99.62 on Monday. The firm has a market capitalization of $79.19 billion, a P/E ratio of 39.07, a price-to-earnings-growth ratio of 4.51 and a beta of 0.31. The company has a debt-to-equity ratio of 11.23, a current ratio of 0.96 and a quick ratio of 0.63. The company has a fifty day moving average price of $90.94 and a 200-day moving average price of $90.29. Colgate-Palmolive Company has a one year low of $75.96 and a one year high of $101.18.

Colgate-Palmolive (NYSE:CL – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.34 billion. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. Colgate-Palmolive’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.91 earnings per share. Equities research analysts expect that Colgate-Palmolive Company will post 3.92 earnings per share for the current fiscal year.

Colgate-Palmolive Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th were given a dividend of $0.53 per share. The ex-dividend date was Tuesday, October 20th. This represents a $2.12 annualized dividend and a yield of 2.1%. Colgate-Palmolive’s payout ratio is presently 83.14%.

Analyst Ratings Changes

A number of brokerages recently issued reports on CL. BNP Paribas Exane restated an “outperform” rating and issued a $108.00 price objective (up from $97.00) on shares of Colgate-Palmolive in a research note on Monday, November 2nd. Piper Sandler cut their target price on shares of Colgate-Palmolive from $98.00 to $95.00 and set an “overweight” rating for the company in a research report on Monday, September 21st. Deutsche Bank reiterated a “buy” rating and issued a $101.00 target price (up from $99.00) on shares of Colgate-Palmolive in a research note on Monday, August 3rd. Barclays boosted their price target on shares of Colgate-Palmolive from $87.00 to $95.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 3rd. Finally, Morgan Stanley upped their price target on shares of Colgate-Palmolive from $104.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Colgate-Palmolive has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Get Our Latest Stock Analysis on CL

Colgate-Palmolive Profile

(Free Report)

Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.

See Also

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.